CD4^+CD25^+调节性T细胞与肿瘤免疫研究进展  

The research progress of CD4^+CD25^+ regulatory T cells and the anti-tumor immune

作　　者：张妍[1] 迟晓燕[2] 崔保霞[1] 

机构地区：[1]山东大学齐鲁医院妇产科,济南250012 [2]青岛市立医院妇产科,青岛266011

出　　处：《生命科学》2010年第4期362-366,共5页Chinese Bulletin of Life Sciences

摘　　要：调节性T细胞(Treg)是一类具有免疫调节功能的细胞群,在机体的免疫耐受中起着关键性作用。它们主要通过细胞-细胞直接接触的方式抑制CD4+和CD8+效应性T细胞的活化和增殖,来调节获得性免疫系统,阻止自身免疫疾病的发生。Treg中以自然产生的CD4+CD25+调节性T细胞(固有Treg细胞)研究最多。在人类,调控效能主要限于CD4+CD25high亚型。由于Treg独特的生物学功能,它在自身免疫性疾病的发生、移植耐受和肿瘤的发生和转归上越来越受到重视。该文就该类细胞的特点及其与肿瘤关系的研究进展作一综述。Treg（Regulatory T cell） is a kind of cells with immune regulation function,which plays a key role in the immunotolerance. They mainly through cells -cells indirect contacting way inhibit the activation and proliferation of CD4＋ and CD8＋ effect T cells,and to regulate the acquired immune systems and prevent the occurrence of autoimmune diseases. The most studied Treg cell type is the naturally occurring CD4＋CD25＋ regulatory T cells （natural Treg cells）. In humans,regulation efficiency mainly is confined to CD4＋CD25high subtype. Due to its unique biological function,Treg in autoimmune disease,transplantation tolerance and cancer＇s incidence and prognosis cause more and more attention. In this paper,the characteristics of such cells,and its relationship with tumor research are reviewed.

关 键 词：CD4+CD25+调节性T细胞 肿瘤 免疫治疗 化疗 

分 类 号：Q2[生物学—细胞生物学] R73-36[医药卫生—肿瘤]